Results 21 to 30 of about 1,905,453 (180)

Development and validation of a novel questionnaire to describe and assess sensations and triggers associated with refractory and unexplained chronic cough [PDF]

BMJ Open Respiratory Research
Introduction Refractory or unexplained chronic cough (RUCC) is a common clinical problem with no effective diagnostic tools. The Sensations and Triggers Provoking Cough questionnaire (TOPIC) was developed to characterise cough in RUCC versus cough in ...
Janelle Yorke, Shilpi Sen, Jenny King, Jacky Smith, Francesca Solari, Chelsea Sawyer, James Wingfield-Digby, Shannon Galgani, Rachel Dockry, Kimberly Holt, Joanne Mitchell, Danielle Birchall   +11 more
doaj   +3 more sources

Efficacy and safety of P2X3 receptor antagonists in refractory or unexplained chronic cough: an updated systematic review and meta-analysis [PDF]

Frontiers in Pharmacology
BackgroundRefractory chronic cough and unexplained chronic cough are increasingly understood as clinical expressions of cough hypersensitivity. P2X3 receptor antagonists have been developed to reduce ATP-mediated airway sensory nerve activation, but ...
Yu-Tong An, Yu-Tong An, Shu-Ze Tang, Shu-Ze Tang, Yi Luo, Le Huang, Xiu-Juan Deng   +6 more
doaj   +3 more sources

Multicentre, 2×2 factorial, randomised, open-label trial of neuromodulators and cough control therapy for refractory or unexplained chronic cough: the FORTITUDE trial protocol [PDF]

BMJ Open
Introduction While clinicians commonly prescribe neuromodulators for the treatment of refractory or unexplained chronic cough, no trials have directly compared these treatments.
Ana Oliveira, Gordon Guyatt, Alan G Kaplan, Anurag Bhalla, Dina Brooks, Elena Kum, Mélanie Bernier, Stephen K Field, Imran Satia, Robert Newman, Simon Couillard, Wafa Hassan, Geoff Strong, Andréanne Côté, Kim Smith, Sue Beaudin, Mustafa Al-Saiedy, Renata Mancopes, Ana Sofia Grave, Danica L Brister, Faye Johnston, Nada Popovic   +21 more
doaj   +3 more sources

Oral Capsaicin as Treatment for Unexplained Chronic Cough and Airway Symptoms [PDF]

CHEST Pulmonary
Background Unexplained chronic cough (UCC) is characterized by persistent coughing without evident medical explanation. Research Question Does daily oral administration of natural capsaicin (chili) improve refractory coughing in patients with UCC?
Ewa Ternesten-Hasséus, Ewa-Lena Johansson, Eva Millqvist   +2 more
exaly   +3 more sources

Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework [PDF]

European Respiratory Review, 2021
Background Cough severity represents an important subjective endpoint in assessing the effectiveness of therapies for patients with chronic cough. Although cough-specific quality of life questionnaires exist, a widely available cough severity instrument ...
Elena Kum, Gordon H. Guyatt, Tahira Devji, Yuting Wang, Layla Bakaa, Lucy Lan, Eva Liu, Alexander Mastrolonardo, Rachel Couban, Paul M. O'Byrne, Imran Satia   +10 more
doaj   +5 more sources

Increased Resistance of the Peripheral Airways in Patients with Unexplained Chronic Cough.

Respiration
Introduction: Troublesome coughing that persists for more than 8 weeks without evident aetiology or effective therapy is termed unexplained chronic cough (UCC). Using impulse oscillometry (IOS) and spirometry, we assessed the functionalities of the large
Ternesten-Hasséus E, Johansson EL, Millqvist E.   +2 more
europepmc   +4 more sources

Validity and Reliability of the Swedish Version of the Leicester Cough Questionnaire in Unexplained Chronic Cough

Respiratory Medicine
BACKGROUND Cough is considered chronic when it lasts for >8 weeks. When no medical explanation can be found it is often called unexplained chronic cough (UCC), which may affect health-related quality of life (HRQOL).
Ewa Ternesten-Hasséus
exaly   +4 more sources

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough [PDF]

ERJ Open Research, 2020
Background We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods COUGH-1 (
David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith   +10 more
doaj   +4 more sources

Chronic and unexplained cough [PDF]

Shortness of Breath, 2014
Cough is a frequent symptom reported in general practice consults. Even though most of the cases concern acute and self limiting episodes, if cough persists a comprehensive diagnostic evaluation should be started. Patients that scarcely respond to empiric therapy or whose symptoms are not clearly referable to one of the most common causes of cough may
Mazzolini, Massimiliano, Zanasi, Alessandro, Alemanni, Matteo, Ierna, Carla Maria Sofia   +3 more
openaire   +3 more sources

Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.

JAMA, 2023
Importance Gefapixant represents an emerging therapy for patients with refractory or unexplained chronic cough. Objective To evaluate the efficacy and tolerability of gefapixant for the treatment of adults with refractory or unexplained chronic cough.
Kum E, Patel M, Diab N, Wahab M, Zeraatkar D, Chu DK, O'Byrne PM, Guyatt GH, Satia I.   +8 more
europepmc   +2 more sources